Johnson & Johnson (TSX:JNJ)
33.97
+0.33 (0.98%)
Oct 26, 2026, 3:55 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,200 employees as of December 28, 2025. The number of employees increased by 100 or 0.07% compared to the previous year.
Employees
138,200
Change (1Y)
100
Growth (1Y)
0.07%
Revenue / Employee
1.02M CAD
Profits / Employee
164.65K CAD
Market Cap
898.73B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 28, 2025 | 138,200 | 100 | 0.07% |
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Johnson & Johnson News
- 36 minutes ago - Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush - TheFly
- 1 hour ago - Johnson & Johnson to Host Enterprise Business Review - Business Wire
- 1 hour ago - Oric Pharmaceuticals selloff brings buying opportunity, says Jones - TheFly
- 21 hours ago - Oric Pharmaceuticals drops after J&J presents prostate cancer drug data - TheFly
- 1 day ago - Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026 - TheFly
- 1 day ago - Johnson & Johnson announces results from Cohort 5 of Phase 1b/2 OrigAMI-4 study - TheFly
- 1 day ago - Johnson & Johnson announces results from Phase 3 PROTEUS substudy - TheFly
- 1 day ago - Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer - GlobeNewsWire